Kornimate/medical-research-clean huggingface dataset:
colonoscopy using motorized spiral enteroscope

Conditions: Colon Disease

Summary: the new technology of the motorized spiral enteroscope, originally developed for deep small bowel enteroscopy, might potentially overcome some limitations of standard colonoscopy.

cecal intubation rate represents a key procedural quality parameter in diagnostic colonoscopy. however, even in experienced hands, a significant percentage of colonoscopies (1.6-16.7%) remain incomplete because of a failure to intubate the cecum. the new technology of the motorized spiral enteroscope, originally developed for deep small bowel enteroscopy, might potentially overcome some limitations of standard colonoscopy. the study aim was to evaluate the feasibility and safety of motorized spiral enteroscopy for difficult colonoscopies.

Eligibility criteria:
inclusion criteria: - indications for spiral colonoscopy as a rescue procedure because of incomplete antecedent colonoscopy exclusion criteria: * age under 18 years * known pregnancy * poor health status (asa classification ≥ 4) * contraindication for sedation or standard colonoscopy * known coagulopathy (inr ≥ 2.0, platelets \< 70 /nl) or anticoagulants other than aspirin * medical history of chronic inflammatory bowel disease or suspected bowel obstruction

Keywords: motorized spiral enteroscopy colonoscopy
androgen deprivation therapy (adt) versus adt plus prostate cryotherapy for metastatic prostate cancer (mpca)

Conditions: Prostate Cancer Metastatic

Summary: patients with primary diagnosed metastatic prostate cancer are randomly divided into two groups. one group receive standard of care adt continually. another group receive adt plus prostate cryotherapy. patients are followed up until their death or withdraw from this study due to other reasons. the primary endpoint of this study is prostate cancer progression-free survival. the secondary endpoint is overall survival, prostate cancer specific survival and health-related quality of life.

ages eligible for study: 18 years and older. genders eligible for study: male. accepts healthy volunteers: no.

Eligibility criteria:
inclusion criteria: * have histologically diagnosed prostate cancer * metastatic disease diagnosed by ct scan, mri scan or bone scan. m stage m1a or m1b according to 2010 american joint committee on cancer (ajcc) stage system * be willing and able to provide written informed consent/assent for the trial * eastern cooperative oncology group (ecog) performance scale status of 0 or 1 * calculator of overall mortality risk at 3 years less than 70%( eur urol. 2016 may 9. pii: s0302-2838(16)30141-5. ) * time interval between hormonal therapy and randomization less than 6 months * can tolerate general anesthesia and cryosurgery * demonstrate adequate organ function exclusion criteria: * according to the doctor's judgment, the patients had any serious illness or other clinical conditions, can't safely undergo the clinical research, any other serious diseases or clinical situation is not limited to the items listed below: * infection ≥ grade 2 according to national cancer institute on the common terminology criteria for adverse events (nci-ctcae) version 4.03, * heart failure (new york heart group nyha) iii or iv, * crohn's disease or ulcerative colitis, * fecal incontinence, * substance abuse, medical, psychological or social problems that may interfere with the evaluation of the results of this study, * the presence of any unstable disease or clinical condition, potential harm to the safety of the subject or influence the subject's compliance. * other malignancies (within 5 years), except for non melanoma skin cancer. patients with other malignancies who survived with effective treatment and randomized to have no evidence of cancer for more than 5 years were allowed to participate in the study * treatment of prostate cancer other than hormonal therapy (except bisphosphonate therapy for bone metastases) * after 6 months of hormonal treatment, the prostate volume greater than 55ml

Keywords: prostate cancer metastatic cryotherapy adt
the anterior approach of the combined lumbar and sacral plexuses block for analgesia of lower limb surgeries

Conditions: Lower Limb Fracture

Summary: lumbosacral plexus block (lspb) has been widely applied in orthopedics departments due to its advantages, including reduction in the application of opiates, decreasing the occurrence of acute pain, promoting early activation, and shortening the time of hospital stay. lspb is a peripheral regional technique of anesthesia and analgesia, that provides a block of the main components of the lumbosacral plexus.

traditional ultrasound-guided lumbar plexus block combined with sacral plexus block requires separate blocks at different sites, requiring the lateral decubitus or prone position, which may be suboptimal in patients with severe pain. we present an anterior approach for combined lumbar and sacral plexus blocks with a one-point puncture.

Eligibility criteria:
inclusion criteria: * asa i-ii. * patients scheduled for unilateral femur or tibial surgery necessitate knee joint intervention * patients who have severe pain hindering changing their position or patients who have spinal fractures or refusing spinal anesthesia. * patients with the capability of communication exclusion criteria: * puncture site infection * patients with coagulation disorders * patients who refuse to participate or withdraw due to personal reasons * allergy to local anesthetics. * past surgery at the site of the block * hip ankylosis * drug abuse * body mass index ≥ 35 kg/m2 * peripheral vascular insufficiency * use of alpha or beta blocker agents * nerve injury or neuropathy of the affected lower limb * cardiovascular or respiratory decompansation
a study of mental health care in people with cancer

Conditions: Breast Cancer; Colorectal Cancer; Lung Cancer; Prostate Cancer

Summary: the purpose of this study is to look at mental health services for adults with depressed mood who were diagnosed with cancer at the age of 65 or older. this study will compare the usual approach for connecting older adults with depressed mood to mental health services with the open door for cancer (od-c) approach. we will find out if the od-c approach is practical and useful for cancer patients who participate in the intervention and for providers who see or treat cancer patients.


Eligibility criteria:
inclusion criteria: patients * per medical record and/or self-report, diagnosed with breast, colorectal, lung, or prostate cancer at age 65 years or older * per medical record and/or self-report, undergoing active cancer treatment (e.g., radiation, chemotherapy, immunotherapy, surgery) or within six months of completing treatment * score of ≥5 on the patient health questionnaire-9 (phq-9) * per self-report, fluent in english\*\* \*\* language verification: prior to enrollment, patients will be asked the following two questions by a clinical research coordinator (crc) to verify english fluency necessary for participation in the study: 1. how well do you speak english? (must respond "very well" or "well" when given the choices of very well, well, not well, not at all, don't know, or refused) 2. what is your preferred language for healthcare? (must respond english) providers * per self-report, works in oncology, nursing, social work, psychology, or psychiatry * per self-report, currently works in oncology at least 50% of the time * per self-report, provided cancer care for at least three years at time of consent * per self-report, fluent in english exclusion criteria: patients * severely cognitively impaired as demonstrated by blessed orientation memory concentration scores of ≥ 11 * per research staff judgment and/or self-report, too ill or weak to complete study procedures * per medical record and/or self-report, receiving hospice care at the time of enrollment * per medical record and/or self-report, currently enrolled in mental health treatment providers * n/a

Keywords: 65 years and older mental health care 23-218
low-level laser therapy and injectable platelet-rich fibrin for thin gingival phenotype.

Conditions: Periodontal Diseases

Summary: management of thin gingival phenotype using non-surgical methods (injection of liquid platelet rich fibrin and exposure to low level laser therapy

thin gingival phenotype can lead to recession and root exposure. liquid prf can be obtained by centrifugion of blood sample on speed 700 rpm for 3 min, then injection of this liquid in the attached gingiva and muco-gingival junction (3 times with 7 days interval) for the first group. the second group will be injected with i-prf in the same method in addition to exposure to low level laser therapy (after each injection of i-prf). this method is expected to increase the thickness of the gingiva.

Eligibility criteria:
inclusion criteria: * free systimatically good oral hygiene gingival thickness less than 1mm exclusion criteria: * pregnancy or lactation pereiodontitis periodontal surgery orthodontic ttt tooth mobility,bruxism,crowding,missing or supernumerary teeth smoking

Keywords: i-prf, thin gingival phenotype low level laser
mechanisms of severe acute influenza consortium (mosaic)

Conditions: Influenza

Summary: the ultimate goal of this collaborative, intensive study is to discover new and effective treatments and to develop better vaccines that can be used in future outbreaks of influenza a. by integrating the information that we will gather, we will create a unique overview of how influenza causes illness and what might be done to improve patient management.

influenza a is one of the best studied viruses, but continues to have a very large impact on human and animal health. in addition to causing outbreaks of winter flu, it sometimes mutates to create a new virus that spreads quickly around the world. it is puzzling that the same virus appears to cause minor or absent symptoms in some people while killing others. much remains to be understood. the investigators have assembled an unprecedented group of internationally renowned scientists from england and scotland who will together focus on studying a few hundred people hospitalised during the current swine flu pandemic. such a large scale project has never before been attempted, but we are now poised to work together and integrate the many recent advances in biomedical science that relate to understanding how influenza causes disease.

Eligibility criteria:
inclusion criteria: * any patient admitted to hospital with suspected or confirmed influenza infection exclusion criteria: * patients who do not give their consent

Keywords: severe acute influenza consortium swine flu influenza a h1n1 hospital admission
genetics of response to canagliflozin

Conditions: Diabetes Mellitus, Type 2

Summary: five daily doses of canagliflozin (300 mg) will be administered to healthy volunteers. pharmacodynamic responses to canagliflozin will be assessed both at 2 days and 6 days after administration of the first dose of canagliflozin. a genome-wide association study (gwas) will be conducted to search for genetic variants that are associated with each of the pharmacodynamic responses to canagliflozin.

after obtaining informed consent, healthy amish research subjects will be screened for eligibility. immediately after obtaining blood samples for baseline clinical chemistry tests wills, patients will initiate 5 days of canagliflozin (300 mg) treatment. fasting blood samples will be obtained to assess pharmacodynamic responses at both 48 hours and 120 hours after initiating canagliflozin. the principal pharmacodynamic responses will include 24 hour urinary excretion of glucose, serum chemistries (phosphorus, fgf23, 1,25-dihydroxyvitamin d, parathyroid hormone (pth), glucagon, beta-hydroxybutyrate, acetoacetate, procollagen type i n-terminal peptide (p1np), and beta-ctx). research subjects will undergo genotyping, and a genome-wide association study will be conducted to search for genetic variants that are associated with pharmacodynamic responses to canagliflozin.

Eligibility criteria:
inclusion criteria: * of amish descent * age 18 or older * bmi: 18-40 kg/m2 exclusion criteria: * known allergy to canagliflozin * history of diabetes, random glucose greater than 200 mg/dl, or hba1c greater than or equal to 6.5% * currently taking diuretics, antihypertensive medication uric acid lowering medications, or other medication that the investigator judges will make interpretation of the results difficult * significant debilitating chronic cardiac, hepatic, pulmonary, or renal disease or other diseases that the investigator judges will make interpretation of the results difficult or increase the risk of participation * seizure disorder * unwilling to go off of vitamin supplements and over the counter medication (except for acetaminophen) for at least two weeks prior to the first home visit and agree to avoid these medications for the duration of the study. * positive urine human chorionic gonadotropin test or known pregnancy within 3 months of the start of the study * estimated glomerular filtration rate less than 60 ml/min * currently breast feeding or breast feeding within 3 month of the start of the study * liver function tests greater than 2 times the upper limit of normal * hematocrit less than 35% * abnormal thyroid hormone stimulating hormone

Keywords: glucosuria sglt2 inhibitors canagliflozin fgf23 parathyroid hormone 1,25-dihydroxyvitamin d glucagon ketone bodies uric acid pharmacogenomics
value of kl-6 in rheumatoid arthritis-associated ild

Conditions: Rheumatoid Arthritis-Associated Interstitial Lung Disease

Summary: evaluation of serum kl6 level in rheumatoid arthritis-associated interstitial lung disease (ra-ild).

rheumatoid arthritis (ra) is one of the most common connective tissue diseases (ctd). its prevalence is increasing worldwide . it is responsible for a considerable number of hospital visits in egyptian hospitals . pumlonary involvement is common in rheumatoid arthritis (ra). interstitial lung disease associated rheumatoid arthritis (ild-ra) is responsible for significant morbidity and mortality . krebs von den lungen 6 (kl-6) is a mucin like glycoprotein that is found mainly on the surface of type ii pneumocytes as well as in bronchiolar epithelial cells . it has chemotactic and anti-apoptotic action on fibroblasts , hence, it is considered as a marker of pulmonary epithelial cell injury . krebs von den lungen-6 (kl6) has been found to be a valuable diagnostic tool in many interstitial lung diseases. kl6 was found to be a valuable prognostic marker, as well as a marker for disease severity in idiopathic pulmonary fibrosis (ipf) . kl6 was found useful as well in predicting in-hospital mortality in patients with acute exacerbation of interstitial lung disease (ae-ild) . kl-6 serum level can serve as a diagnostic marker for connective tissue disease-associated interstitial lung disease (ctd-ild). it can be used to monitor effectiveness of medical treatment and patient response to pulse therapy . its value in rheumatoid arthritis-associated interstitial lung disease (ra-ild) has not yet been adequately investigated.

Eligibility criteria:
diagnosis of ra will be based on american college of rheumatology/european league against rheumatism (acr-eular) classification criteria 2010. inclusion criteria: * all patients have rheumatoid arthritis-associated interstitial lung disease exclusion criteria: * patients with any evidence of infection will be excluded.
reasons for changing hormonal therapy of advanced breast cancer

Conditions: Breast Cancer

Summary: breast cancer is the leading type of cancer in women. although big advance in diagnostics and treatment of early and breast cancer has been made in recent years breast cancer still has a significant mortality rate. a number of treatment modalities exist for postmenopausal women with advanced breast cancer. the treatment modality is chosen based on patient and tumour characteristics. hormonal treatment is preferred and recommended in women with hormone sensitive breast cancer (esmo, cecog and nccn guidelines). tumor markers are an established method of monitoring systemic therapies in various cancers. tumor markers ca 15-3 and cea are used in clinical practice to monitor treatment efficacy of metastatic breast cancer. blood levels of tumor markers are widely used to assess response/progression to treatment and guide therapy change. treatment efficacy is assessed by imaging methods in clinical studies. change of therapy in clinical study is usually done when progression based on recist criteria is found. hormonal treatment has slower onset of effect compared with chemotherapy that can last several weeks. also when a new therapy is started spurious early rises may occur. therefore rising levels of tumor markers during the first weeks of new hormonal therapy are not necessarily sign of progression and should not be the only guidance for treatment change. evidence of treatment efficacy form clinical studies and treatment change is based on imaging techniques.


Eligibility criteria:
inclusion criteria: * women with at least two finished lines of hormonal treatment for advanced breast cancer tumor markers (cea. ca15-3) values available at the time of onset and discontinuation of therapy imaging methods results available at the time of onset and discontinuation of therapy exclusion criteria: * none

Keywords: advanced breast cancer hormonal treatment
prevention of photoparoxysmal abnormalities by mozart k448

Conditions: Photoparoxysmal Abnormalities; Epilepsy; Seizures

Summary: the purpose of this clinical trial is to examine the effect of non-invasive cortical activation by specific patterned auditory stimulation (mozart k448- piano sonata for two hands in d major), in altering or eliminating photoparoxysmal abnormalities. recent work has indicated that such evoked activity (i.e. by specific music) can result in significant reductions, or even complete termination of epileptiform activity and/or seizures across a broad range of individuals with epilepsy. a hypothesis is generated that specific music activation would beneficially effect photoparoxysmal based epileptiform abnormalities.

non-pharmacologic, non-surgical treatments for seizures and epilepsy are of increasing importance, given the potential side effects as well as lack of complete seizure control with such treatments. based on previous studies demonstrating an anti-convulsant and anti-epileptiform effect achieved in subjects by music exposure, it is proposed that specific musical stimuli may causally result in widely distributed cortical activation in such a fashion as to effectively prevent or terminate epileptiform abnormalities in subjects with photosensitive epilepsy. we will investigate the effect of specific musical stimulation (mozart k448) to reduce or prevent photoparoxysmal abnormalities in subjects. primary outcome will be evaluated in 3 groups, assessing alteration/cessation of photic-induced abnormalities during: 1. treatment: music exposure to mozart k448, vs. 2. placebo: music exposure to beethoven's für elise for piano, vs. 3. control: no music exposure.

Eligibility criteria:
inclusion criteria: * age 5-17 years, inclusive * female or male with photoparoxysmal epilepsy clinical history, and at least one seizure, as defined by the international league against epilepsy (international classification of epilepsies and epileptic syndromes; commission on classification and terminology of the international league against epilepsy 1989) * abnormal eeg consistent with features of photoparoxysmal epilepsy: occipital based epileptiform abnormalities with otherwise normal background interictal eeg; * on \< or equal to 2 anti-seizure medications \[range 0-2 aeds\] exclusion criteria: * history of a generalized convulsion provoked by photic stimulation; * inability to complete and/or comply with study protocol

Keywords: children's health pediatrics epilepsy photoparoxysmal photosensitive music mozart k-448
pocone-ubit-ir300 pediatric comparison study

Conditions: Bacterial Infection Due to Helicobacter Pylori (H. Pylori)

Summary: the purpose of this study is to compare between the pocone® to the ubit®-ir300 in measuring 13co2/12co2 ratio in breath samples when used together with the breathtek® ubt (urea breath test) kit and the puhr-ca web-based software program in identifying h. pylori infection in pediatric subjects.

the same patients will be tested on both the pocone® and ubit®-ir300. if the patients test positive for h. pylori, they will be given eradication medication and brought back in for a re-test.

Eligibility criteria:
inclusion criteria: 1. male or female subject ages 3 to 1711/12 years. 2. subject with upper gastrointestinal signs and symptoms (e.g., abdominal pain/discomfort, bloating, nausea, or vomiting, etc.) 3. subject and/or parent/legal guardian is capable of giving assent or consent. 4. subject is able to complete the urea breath test by investigator's assessment. exclusion criteria: 1. subject is hypersensitive to mannitol, citric acid and/or aspartame. 2. previous diagnosis of phenylketonuria (pku. 3. subject with difficulty swallowing or who may be at high risk for aspiration due to medical or physical conditions. 4. subjects with ongoing respiratory conditions or on bronchodilators that may compromise the collection of breath samples. 5. subjects with severe chronic illness (e.g., crohn's disease, leukemia, kidney diseases, etc.) 6. administration of bismuth preparations (e.g., pepto-bismol®) at anytime within 14 days prior to the testing. 7. administration of antibiotics (e.g., amoxicillin, tetracycline, metronidazole, clarithromycin, azithromycin, etc.) therapy at anytime within 14 days prior to the testing. 8. administration of proton pump inhibitors (ppi; e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, pantoprazole, etc.) at anytime within 14 days prior to the testing. 9. administration of histamine h2 receptor antagonist (h2ra; e.g., ranitidine, cimetidine, famotidine, nizatidine, etc.) at anytime within 24 hours prior to the testing. 10. treatment for eradication of h pylori within 28 days before testing or retesting. 11. participation in a drug or device study within 30 days of testing

Keywords: helicobacter pylori